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Background
Erythropoietin (EPO) is known as a regulating hormone for
production of red blood cells called Erythropoiesis. Some
studies have shown that erythropoietin have some non-
hematopoietic protective effects on ischemia-reperfusion
injury in myocardial cells. We evaluated the effect of exo-
genous EPO infusion on reducing ischemia-reperfusion
injuries and improvement of cardiac function by echocar-
diography shortly after coronary artery bypass graft
surgery.
Methods
43 patients were joined the study and randomly divided in
two groups, EPO group: receiving standard medication
and CABG surgery plus 700 IU/kg erythropoietin (PD
Poietin, puyeshdaroo, Iran) and control group: receiving
standard medication and CABG surgery plus 10cc normal
saline as placebo. The cardiac function was assessed by
Echocardiography in all patients in before, 4 days after and
also 30 days after CABG operation.
Results
Echocardiography indicated that EF had no differences
between EPO and control group at 4 days (47.05±6.29 vs
45.90±4.97, P=0.334) or 30 days after surgery (47.27±28 vs
46.62±5.7, P=0.69). There were no differences between
EPO and control group in wall motion score index at
4 days (P=0.83) or 30 days after surgery (P=0.902). In EPO
group: Left ventricle end systolic and diastolic diameter
(LVESD, LVEDD) had reduction, as compared to control
group.
Conclusions
Our data suggest that peri-operatively exogenous EPO
infusion can’t improve ventricular function and Wall
motion index in first weeks after surgery. But as compared
to control group, reduction in LVEDD and LVESD at
4 days or 30 days after CABG surgery in EPO group sug-
gested that EPO had correlation with reduction of myo-
cytes remodeling and reperfusion injury early after CABG
surgery.
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